Nightingale Health and U.S.-based Phenome Health announce a partnership to strive towards the most transformational change in the history of healthcare

Nightingale Health Plc

Press release

6 August 2024 at 6:00 p.m. (EEST)

 

Nightingale Health Plc (“Nightingale Health”), a Finnish pioneer in disease-risk detection and preventative health, and Phenome Health, a U.S.-based non-profit research organization and pioneer in multi-omic health innovations announce their collaboration on research studies, population health programs, and healthcare initiatives. 

 

The two organisations share a common vision of preventative health. Many chronic conditions, such as diabetes and heart disease, are at epidemic levels in the United States and Europe. An estimated 80% of these healthcare dollars are spent treating potentially preventable diseases. The healthcare industry urgently needs a shift towards keeping people healthy and preventing disease instead of treating diseases.

 

Phenome Health, founded by Dr. Leroy Hood, a world-renowned scientist and recipient of the National Medal of Science in 2011, is taking a novel data-driven approach that combines different molecular and digital health data modalities to enhance the understanding of biology and human health ultimately leading to a world where we could prevent diseases before they begin.

 

“Shifting healthcare from a disease orientation to a focus on wellness and prevention has the potential to be the most transformational change in the history of medicine. Our partner ecosystem is working to catalyze this transformation through a data-driven, systems approach to health and wellness.” Says Dr. Leroy Hood, CEO and Founder of Phenome Health.

 

“Nightingale’s technology is the first ‘omics’ technology that has been adopted for routine clinical use and it has started the transformation towards preventative healthcare. This is why we strongly believe that Nightingale provides one of the key technologies when building the future of healthcare and we are delighted to integrate the technology into our partner ecosystem” continues Dr. Hood.

 

Phenome Health is already partnering with some of the leading organisations in the U.S. such as the Buck Institute for Research on Aging, Guardian Research Network, Posit Science, and Google, putting together the capabilities of many industry-leading experts and research organizations that will create a transformative opportunity in healthcare.

 

“Over the past ten years, Nightingale has created a technology that enables disease risk detection and preventative healthcare applications in unprecedented scale and efficiency. In the next ten years, we need to integrate the efforts of the global leaders in the field and create a world where advanced disease prevention and living long and healthy is the new normal. We are delighted to partner with Phenome Health - one of the global trailblazers in the next generation of preventative health – and join the ecosystem of some of the world’s strongest organizations to build a healthier future”, says Teemu Suna, CEO and Founder of Nightingale Health.   

 

Nightingale Health and Phenome Health have signed a Memorandum of Understanding (MOU) to state their intentions to undertake collaborations in both multi-omic research studies and the development of data-driven health and wellness programs incorporating multi-omic data for healthcare systems, employers, insurers, or other entities.

One of the initiatives the parties intend to collaborate on is the Human Phenome Initiative that Phenome Health is pioneering, aiming to gather one million participants analyzed over 11 years, returning the data-rich actionable possibilities to patients. The two companies also plan to explore opportunities to provide metabolomic testing in large U.S. healthcare systems. 

The parties expect to enter into definitive agreements and announce major steps in the partnership at a later date. 

 

 

For further information, please contact:

Teemu Suna, CEO
[email protected]

 

 

About Phenome Health

 

Phenome Health was established by internationally acclaimed scientist and entrepreneurial visionary, Lee Hood, to contribute solutions to major challenges causing a crisis in healthcare. The aging population and other factors are driving an explosion of chronic disease that largely contribute to increasing costs at an unsustainable rate in a healthcare system not equipped to solve these problems without a radical paradigm change - namely shifting from a reactive system that focuses on treating disease to a proactive system focused on optimizing health. Phenome Health and its partners strive to accelerate this shift through a systematic approach to define health, develop a disease-agnostic discovery framework to understand how and why people transition to disease, and identify new approaches to prevent and reverse disease development. Our ambitious strategy leverages advancements in biotechnologies, computer science and AI to capture and interpret high-dimensional data on a large swath of individuals, representing human diversity, to invent the solutions needed to solve the healthcare crisis. We call this opportunity, The Human Phenome Initiative (HPI).

 

About Nightingale Health

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com